Summit Therapeutics's latest marketcap:
As of 07/17/2025, Summit Therapeutics's market capitalization has reached $20.52 B. According to our data, Summit Therapeutics is the 1055th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 20.52 B |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -240,755,000 |
| Shares Out | 742.67 M |
| EPS (ttm) | -0.34 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/05/2025 |
Summit Therapeutics's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/17/2025 | $20.52 B | 37.47% | 1055 |
| 12/31/2024 | $13.16 B | 619.43% | 1355 |
| 12/29/2023 | $1.83 B | 113.79% | 5944 |
| 12/30/2022 | $855.6 M | 225.45% | 9091 |
| 12/31/2021 | $262.9 M | -32% | 17234 |
| 12/31/2020 | $386.6 M | 653.61% | 13090 |
| 12/31/2019 | $51.3 M | 203.55% | 21783 |
| 12/31/2018 | $16.9 M | -87.66% | 26039 |
| 12/29/2017 | $137 M | 30.6% | 16393 |
| 12/30/2016 | $104.9 M | -21.83% | 15735 |
Company Profile
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing patient-friendly therapies in the United States and the United Kingdom.
Key Development Candidate
The company's lead candidate, ivonescimab, is an innovative bispecific antibody designed for immunotherapy. It works by blocking PD-1 while also targeting anti-angiogenesis. Currently, ivonescimab is in Phase III clinical trials for treating non-small cell lung cancer.
Strategic Partnerships
Summit Therapeutics has a collaboration and license agreement with Akeso, Inc. and its affiliates to advance the development and commercialization of ivonescimab.
Company Background
- Founded: 2003
- Headquarters: Miami, Florida
Frequently Asked Questions
-
What is Summit Therapeutics's (SMMT) current market cap?As of 07/17/2025, Summit Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $20.52 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Summit Therapeutics (SMMT) rank globally by market cap?Summit Therapeutics global market capitalization ranking is approximately 1055 as of 07/17/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.